Akari Therapeutics (AKTX) Stock Price, News & Analysis

Company Overview

Akari Therapeutics, Plc (NASDAQ: AKTX) is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on regulating the complement system and inflammatory pathways that contribute to tissue damage.

Akari’s lead investigational product is nomacopan, a recombinant small protein designed to inhibit complement component 5 (C5) and leukotriene B4 (LTB4). The company is also developing a long-acting formulation known as PAS-nomacopan. These programs have been evaluated or are being developed for conditions including pediatric hematopoietic stem cell transplant-associated thrombotic microangiopathy and bullous pemphigoid.

Akari Therapeutics conducts its development activities through operations and clinical programs involving the United States and the United Kingdom. The company’s therapies remain investigational and are subject to clinical testing and regulatory review; no assurance can be given that they will receive approval or become commercially available.

Key Stats

• Today's Range: $7.00 to $8.89
• 50-Day Range: $7.00 to $11.47
• 52-Week Range: $3.02 to $33.60
• Volume: 55,689 shs
• Average Volume: 277,131 shs
• Market Capitalization: $20.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.33
• Consensus Rating: Moderate Buy

Akari Therapeutics Stock Analysis - MarketRank™

Akari Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 499th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Akari Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Akari Therapeutics has a consensus price target of $32.33, representing about 265.8% upside from its current price of $8.84.

Amount of Analyst Coverage

Akari Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Akari Therapeutics has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.07% of the float of Akari Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Akari Therapeutics has a short interest ratio ("days to cover") of 0.23, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Akari Therapeutics has recently increased by 34.99%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akari Therapeutics does not currently pay a dividend.

Dividend Growth

Akari Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.61

News Sentiment

Akari Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Akari Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Akari Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.00% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

5.06% of the stock of Akari Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 3/31/2020
• Today: 10/15/2026
• Next Earnings (Estimated): 12/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AKTX
• CIK: 1541157
• Web: www.akaritx.com
• Phone: (929) 274-7510
• Fax: 646-843-9352
• Employees: 5
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Akari Therapeutics: $32.33
• High Price Target: $40.00
• Low Price Target: $27.00
• Potential Upside/Downside: +265.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -147.45%
• Return on Assets: -74.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.60
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $24.75 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 2,290,000
• Free Float: 1,600,000
• Market Cap: $20.24 million
• Optionable: Not Optionable
• Beta: 1.43